Junji Suzuki

About

Dr. Junji Suzuki is a leading figure in the advancement of radiation oncology, with a focused expertise in ultrahypofractionated treatments for prostate cancer. His research critically evaluates and compares the most sophisticated delivery technologies, including robotic radiosurgery systems, multileaf collimators (MLCs), and high-dose-rate brachytherapy (HDR-BT). Dr. Suzuki’s major contribution lies in providing the clinical evidence needed to optimize treatment planning. His seminal 2017 work demonstrated the clinical superiority of MLCs over circular collimators for prostate SBRT, a finding that has shaped modern clinical protocols (12 citations). More recently, his 2023 comparative study between HDR-BT and robotic SBRT offers crucial guidance for selecting the most effective ultrahypofractionation method (6 citations). By systematically benchmarking these advanced techniques, Dr. Suzuki directly informs clinical decision-making, helping to maximize tumor control while minimizing toxicity. His work is essential reading for medical physicists and radiation oncologists striving to refine stereotactic body radiotherapy and brachytherapy for prostate cancer patients.

Research Focus

Key Achievements

Top Papers

1. 1
   Clinical usefulness of <scp>MLC</scp>s in robotic radiosurgery systems for prostate <scp>SBRT</scp>

   12 citations · 2017
2. 2
   Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer

   6 citations · 2023

Key Collaborators

Contact & Links